Abdelmoula Leila Cheikhrouhou, Ben M'barek Rim, Ben Hadj Yahia Chiraz, Tekaya Raoudha, Testouri Nadia, Chaabouni Lilia, Zouari Rafik
Universite Tunis, El Manar, Tunisie.
Tunis Med. 2011 Jun;89(6):511-6.
AIM: Report of bisphosphonates indications for osseous diseases other than osteoporosis. METHODS: Narrative review of the literature. RESULTS: Bisphosphonates represent a new medication which is increasingly used. Besides osteoporosis, it is indicated as first choice in different bone diseases such as Paget's disease and the prevention of bone complications in tumoral osteolysis. Bisphosphonates' efficiency has been proven in other pathologies: the fibrous dysplasia and the osteogenesis imperfecta. More over, many studies are driven having for goal to show the efficiency of bisphosphonates in the algoneurodystrophy, non corticosteroid-treated osteoporosis in chronic inflammatory rheumatism and aseptic osteonecrosis. CONCLUSION: Bisphosphonates are a powerful inhibition of osseous resoption frestable indicated for osteoporosis. Their indications were retended to paget's disease, malignant hypercalcemia, and osseous complications of malignant osterlysis.
目的：报告双膦酸盐在骨质疏松症以外的骨疾病中的应用指征。 方法：对文献进行叙述性综述。 结果：双膦酸盐是一种使用日益广泛的新型药物。除骨质疏松症外，它还是不同骨疾病（如佩吉特病）的首选药物，并用于预防肿瘤性骨溶解中的骨并发症。双膦酸盐在其他病症（骨纤维发育不良和成骨不全）中的疗效已得到证实。此外，许多研究旨在证明双膦酸盐在痛性神经营养不良、慢性炎症性风湿病中未经皮质类固醇治疗的骨质疏松症和无菌性骨坏死中的疗效。 结论：双膦酸盐是一种强大的骨吸收抑制剂，适用于骨质疏松症。其应用指征已扩展至佩吉特病、恶性高钙血症和恶性骨溶解的骨并发症。
Rev Chir Orthop Reparatrice Appar Mot. 1998-11
Ann N Y Acad Sci. 2010-9-28
Am J Ther. 2012-5
Joint Bone Spine. 2002-1
Z Orthop Ihre Grenzgeb. 2006
Pediatr Endocrinol Rev. 2005-12
Curr Opin Rheumatol. 2000-7
J Oral Maxillofac Surg. 2009-5
Zotero 插件